Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 30.24%, which has investors questioning if this is right time to ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

Many variations on this as combo therapy of chk1 and Pd-1 of great importance ... to a deal both development of the CHK1 inhibitor and Wee1 inhibitor were halted? This at the time when GSK pushed ...

ACR-368, a CHK1/2 inhibitor, is Acrivon’s most advanced ... Acrivon’s second clinical-stage asset, ACR-2316, is a dual WEE1/PKMYT1 inhibitor that has been progressing ahead of schedule.

ACR-368, specifically targeting CHK1/2i, and ACR-2316, aimed at WEE1/ PKMYT1i, are central to Acrivon’s pipeline and are being closely watched by investors and analysts alike for their potential ...

ACR-368, a CHK1/2 inhibitor, is Acrivon’s most advanced clinical asset ... Acrivon’s second clinical-stage asset, ACR-2316, is a dual WEE1/PKMYT1 inhibitor that has been progressing ahead of schedule.

After hours: March 24 at 7:42:57 PM EDT Loading Chart for ACRV ...